Affiliation:
1. College of Food Science and Nutritional Engineering, China Agricultural University, Beijing 100083, China
2. Key Laboratory of Precision Nutrition and Food Quality, Department of Nutrition and Health, China Agricultural University, Beijing 100083, China
3. Food Laboratory of Zhongyuan, Luohe 462300, China
Abstract
Inflammatory bowel disease (IBD) is a chronic disease associated with overactive inflammation and gut dysbiosis. Owing to the beneficial effects of bifidobacteria on IBD treatment, this study aimed to investigate the anti-inflammation effects of an exopolysaccharide (EPS)-producing strain Bifidobacterium pseudocatenulatum Bi-OTA128 through a dextran sulfate sodium (DSS)-induced colitis mice model. B. pseudocatenulatum treatment improved DSS-induced colitis symptoms and maintained intestinal barrier integrity by up-regulating MUC2 and tight junctions’ expression. The oxidative stress was reduced after B. pseudocatenulatum treatment by increasing the antioxidant enzymes of SOD, CAT, and GSH-Px in colon tissues. Moreover, the overactive inflammatory responses were also inhibited by decreasing the pro-inflammatory cytokines of TNF-α, IL-1β, and IL-6, but increasing the anti-inflammatory cytokine of IL-10. The EPS-producing strain Bi-OTA128 showed better effects than that of a non-EPS-producing stain BLYR01-7 in modulating DSS-induced gut dysbiosis. The Bi-OTA128 treatment increased the relative abundance of beneficial bacteria Bifidobacterium and decreased the maleficent bacteria Escherichia-Shigella, Enterorhabuds, Enterobacter, and Osillibacter associated with intestinal inflammation. Notably, the genera Clostridium sensu stricto were only enriched in Bi-OTA128-treated mice, which could degrade polysaccharides to produce acetic acid and butyrate in the gut. This finding demonstrated a cross-feeding effect induced by the EPS-producing strain in gut microbiota. Collectively, these results highlighted the anti-inflammatory effects of the EPS-producing strain B. pseudocatenulatum Bi-OTA128 on DSS-induced colitis, which could be used as a candidate probiotic supporting recovery from ongoing colitis.
Funder
National Key R&D Program of China
Subject
Food Science,Nutrition and Dietetics
Reference40 articles.
1. Cytokines in inflammatory bowel disease;Neurath;Nat. Rev. Immunol.,2014
2. Li, L., Peng, P., Ding, N., Jia, W., Huang, C., and Tang, Y. (2023). Oxidative Stress, inflammation, gut Dysbiosis: What can polyphenols do in inflammatory bowel disease?. Antioxidants, 12.
3. Twenty-first century trends in the global epidemiology of pediatric-onset inflammatory bowel disease: Systematic review;Kuenzig;Gastroenterology,2022
4. Ulcerative colitis;Ordas;Lancet,2012
5. Perspectives on current and novel treatments for inflammatory bowel disease;Na;Gut Liver,2019